TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT00821717

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.
“Positive FAIR-HF study data are available, this study is identical as EFFICACY-HF. Due to low recruitment in EFFICACY-HF the decision was made to terminate it.”

The sponsor’s own words in the registry.

Life of this trial

20082009201020112012Started2008-12Registered2009-01-07Primary completion2009-10Stopped2011-01

Vital statistics

Status
Terminated
Phase
Phase 3
Sponsor
Vifor Pharma
Sponsor type
Industry
Conditions
Chronic Heart Failure; Iron Deficiency; Iron Deficiency Anemia; Anaemia
Interventions
Ferinject ® (Ferric carboxymaltose); Normal saline (0.9%)
Participants
35
Sites
41
Countries
Denmark, France, Germany, Israel, Netherlands

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.